<unk> treated patients are at an increased risk of thromboembolic events. There was a higher incidence of arterial and venous thrombotic and thromboembolic events in patients who received<unk> compared to placebo treated patients in the ATHOS-3 study 13% (21/163 patients) vs. 5% (8/158 patients). It is recommended that patients be on concurrent venous thromboembolism prophylaxis. Other adverse reactions include thrombocytopenia, tachycardia, fungal infection, delirium, acidosis, hyperglycemia, and peripheral ischemia.<unk> acts on<unk>  receptor (AT1) on presynaptic adrenergic nerves → release of catecholamine → excessive catecholamine can be harmful as it can cause myocyte necrosis.
Angiotensin II 
Endothelin
Prorenin
Adrenomedullin
Prostacyclin
Vasopressin 
Vasopressin
Endrin